These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34180037)

  • 1. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
    Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
    Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
    Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
    Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
    Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
    Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
    Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
    Blotner S; Chen LC; Ferlini C; Zhi J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
    Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
    Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
    Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral idasanutlin in patients with polycythemia vera.
    Mascarenhas J; Lu M; Kosiorek H; Virtgaym E; Xia L; Sandy L; Mesa R; Petersen B; Farnoud N; Najfeld V; Rampal R; Dueck A; Hoffman R
    Blood; 2019 Aug; 134(6):525-533. PubMed ID: 31167802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
    So WV; Ou Yang TH; Yang X; Zhi J
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):209-213. PubMed ID: 30511219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
    Higgins B; Glenn K; Walz A; Tovar C; Filipovic Z; Hussain S; Lee E; Kolinsky K; Tannu S; Adames V; Garrido R; Linn M; Meille C; Heimbrook D; Vassilev L; Packman K
    Clin Cancer Res; 2014 Jul; 20(14):3742-52. PubMed ID: 24812409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
    Mascarenhas J; Passamonti F; Burbury K; El-Galaly TC; Gerds A; Gupta V; Higgins B; Wonde K; Jamois C; Kovic B; Huw LY; Katakam S; Maffioli M; Mesa R; Palmer J; Bellini M; Ross DM; Vannucchi AM; Yacoub A
    Blood Adv; 2022 Feb; 6(4):1162-1174. PubMed ID: 34933330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
    Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
    Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
    Corbali MO; Eskazan AE
    Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
    Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
    Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
    Infante JR; Weiss GJ; Jones S; Tibes R; Bauer TM; Bendell JC; Hinson JM; Von Hoff DD; Burris HA; Orlemans EO; Ramanathan RK
    Eur J Cancer; 2014 Nov; 50(17):2897-904. PubMed ID: 25262379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.